Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GRATITUDE II: Miricorilant in AIWG
NCT04524403Phase 2Completed
- Sponsor
- Corcept Therapeutics
- Start
- Sep 2020
- Primary completion
- Jul 2022
- Modality
- Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of miricorilant in antipsychotic-induced weight gain (AIWG), sponsored by Corcept Therapeutics. Started Sep 2020; status: completed.
02
Drugs
miricorilant
03
Conditions
antipsychotic-induced weight gain (AIWG)
Beyond the preview
Go deeper on NCT04524403.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04524403.